Newborn Screening and Birth Prevalence for Spinal Muscular Atrophy in the US
Authors:
Open Access
- 1 September 2024
- journal article
- letter
- Published by American Medical Association (AMA) in JAMA Pediatrics
- Vol. 178 (9) , 946-949
Abstract
Spinal muscular atrophy (SMA) is an autosomal recessive disease resulting in progressive motor neuron death, muscle denervation, and weakness.1 Rapid, widespread implementation of newborn screening (NBS) for SMA in the US since 2018 has facilitated the collection of precise SMA data, including birth prevalence.2 Cure SMA, a US-based patient advocacy organization supporting people with SMA, partnered with state public health laboratories (PHLs) to collect data on infants who were screened for SMA and confirmed to have SMA diagnosis. This study estimated the birth prevalence of SMA and evaluated the distribution of SMN2 copy number in US newborns with SMA.Keywords
This publication has 5 references indexed in Scilit:
- A multi-source approach to determine SMA incidence and research ready populationJournal of Neurology, 2017
- Committee Opinion No. 691: Carrier Screening for Genetic ConditionsObstetrics & Gynecology, 2017
- Spinal muscular atrophy: Diagnosis and management in a new therapeutic eraMuscle & Nerve, 2014
- Pan-ethnic carrier screening and prenatal diagnosis for spinal muscular atrophy: clinical laboratory analysis of >72 400 specimensEuropean Journal of Human Genetics, 2011
- Technical standards and guidelines for spinal muscular atrophy testingGenetics in Medicine, 2011